NPI: 1023061405 · BIRMINGHAM, AL 35243 · General Acute Care Hospital · NPI assigned 05/18/2006
Authorized official LALOR, PAULA controls 20+ related entities in our dataset. Read more
| Authorized Official | LALOR, PAULA (DIRECTOR/DELEGATED OFFICIAL) |
| NPI Enumeration Date | 05/18/2006 |
Other providers sharing the same authorized official: LALOR, PAULA
| Year | Claims | Total Paid |
|---|---|---|
| 2018 | 9,104 | $129K |
| 2019 | 9,019 | $116K |
| 2020 | 5,688 | $66K |
| 2021 | 6,438 | $97K |
| 2022 | 6,921 | $124K |
| 2023 | 6,996 | $191K |
| 2024 | 6,063 | $176K |
| Code | Description | Claims | Beneficiaries | Total Paid |
|---|---|---|---|---|
| 99284 | 7,061 | 6,252 | $428K | |
| 99283 | 4,766 | 4,308 | $178K | |
| 85025 | 11,323 | 9,784 | $85K | |
| 80053 | 9,032 | 7,662 | $82K | |
| 87591 | 1,061 | 1,016 | $31K | |
| 87070 | 2,037 | 1,978 | $23K | |
| 86780 | 855 | 818 | $15K | |
| 99285 | 46 | 43 | $11K | |
| 87086 | 758 | 648 | $8K | |
| 87389 | 159 | 152 | $3K | |
| 87804 | 167 | 151 | $3K | |
| 84443 | 229 | 220 | $3K | |
| 81001 | 758 | 650 | $3K | |
| 86762 | 114 | 111 | $2K | |
| 86592 | 376 | 350 | $2K | |
| 80061 | 144 | 139 | $1K | |
| 87340 | 113 | 110 | $1K | |
| 86850 | 247 | 234 | $1K | |
| 84439 | 213 | 206 | $1K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 28 | 27 | $1K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 44 | 27 | $1K |
| 85027 | 391 | 283 | $1K | |
| 93005 | 95 | 81 | $916.26 | |
| 71045 | 209 | 178 | $898.11 | |
| 0002A | 28 | 27 | $880.00 | |
| 87081 | 77 | 77 | $769.74 | |
| 87502 | 17 | 17 | $759.50 | |
| 85014 | 265 | 246 | $746.06 | |
| 80164 | 69 | 67 | $706.70 | |
| 86787 | 40 | 40 | $698.36 | |
| 87428 | 15 | 15 | $679.00 | |
| 82105 | 29 | 27 | $586.36 | |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 35 | 30 | $514.10 |
| 82947 | 126 | 111 | $453.00 | |
| 86900 | 143 | 138 | $417.67 | |
| 86901 | 143 | 138 | $402.39 | |
| 0001A | 12 | 12 | $360.00 | |
| 80305 | 39 | 36 | $342.93 | |
| 83036 | 48 | 46 | $254.52 | |
| 84484 | 47 | 38 | $253.78 | |
| 87661 | 13 | 12 | $234.24 | |
| 87430 | 21 | 16 | $224.56 | |
| 82607 | 14 | 14 | $219.90 | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 13 | 13 | $192.50 |
| 83020 | 13 | 13 | $189.90 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | 46 | 38 | $184.64 |
| 81025 | 46 | 39 | $175.32 | |
| 83690 | 43 | 37 | $171.65 | |
| 83655 | 15 | 12 | $168.20 | |
| 81003 | 82 | 79 | $131.60 | |
| 82306 | 14 | 14 | $107.76 | |
| 82247 | 17 | 17 | $102.40 | |
| 85018 | 26 | 25 | $86.75 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 26 | 12 | $65.00 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | 71 | 65 | $44.45 |
| 87491 | 1,072 | 1,029 | $37.03 | |
| 36415 | 6,506 | 5,396 | $20.16 | |
| G0475 | Hiv antigen/antibody, combination assay, screening | 674 | 655 | $0.00 |
| 0241U | 112 | 103 | $0.00 | |
| 91300 | 46 | 44 | $0.00 |